Canaccord Genuity reiterates a 'Buy' on Aegerion Pharmaceuticals (AEGR); 78-Week Extension Data: Durable Lomitapide Efficacy, Safety
Tweet
Share
E-mailGet Alerts AEGR Hot Sheet
Price: $1.97 --0%
Rating Summary:
8 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Aegerion Pharmaceuticals (NASDAQ: AEGR) price target of $24.00.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on lomitapide potential as best-in-class HoFH drug. Lomitapide is AEGR’s Phase 3 drug for HoFH, a rare genetic disease that causes extremely high LDLs. We think lomitapide is the best-in-class HoFH drug in terms of tolerability and efficacy vs. ISIS/SNY’s Phase 3 mipomersen. AEGR will submit lomitapide’s NDA/MAA in Q1/12, and we expect FDA approval in Q3/12.x"
"Last Friday’s 78--week lomitapide pivotal extension data showed steady safety and efficacy in HoFH (Fig. 1). Mean LDL baseline reduction at week 78 was slightly lower at 38% (vs. 44% at week 56). Mean liver fat, lomitapide’s main safety concern, was slightly higher at 8.2% (vs. 7.3% at Tx week 56), but still lower than peak (9.0% at Tx week 26). We think this variation is minor with little clinical meaningfulness."
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $16.11 yesterday.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on lomitapide potential as best-in-class HoFH drug. Lomitapide is AEGR’s Phase 3 drug for HoFH, a rare genetic disease that causes extremely high LDLs. We think lomitapide is the best-in-class HoFH drug in terms of tolerability and efficacy vs. ISIS/SNY’s Phase 3 mipomersen. AEGR will submit lomitapide’s NDA/MAA in Q1/12, and we expect FDA approval in Q3/12.x"
"Last Friday’s 78--week lomitapide pivotal extension data showed steady safety and efficacy in HoFH (Fig. 1). Mean LDL baseline reduction at week 78 was slightly lower at 38% (vs. 44% at week 56). Mean liver fat, lomitapide’s main safety concern, was slightly higher at 8.2% (vs. 7.3% at Tx week 56), but still lower than peak (9.0% at Tx week 26). We think this variation is minor with little clinical meaningfulness."
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $16.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
